Erloren 150mg Tablet 7pcs

✔️ Uses of Erloren 150

• Non-small cell lung cancer
• Pancreatic cancer

✔️ Common side effects (>20%) include: Erloren 150

• Rash, diarrhea, anorexia, fatigue, dyspnea, cough, nausea, and vomiting.

Serious adverse reactions may include:

• Interstitial Lung Disease (ILD)
• Renal failure
• Hepatotoxicity (with or without hepatic impairment)
• Gastrointestinal perforations
• Bullous or exfoliative skin disorders
• Myocardial infarction or ischemia
• Cerebrovascular accidents
• Microangiopathic hemolytic anemia with thrombocytopenia
• Ocular disorders
• Hemorrhage in patients taking warfarin

✔️ Quick Suggestions:

• Erloren treats non-small cell lung cancer that is advanced or has spread to other parts of the body.
• Take it 1 hour before or 2 hours after a meal for optimal effectiveness.
• Diarrhea is a possible side effect. Stay hydrated and consult your doctor if it persists or if you notice blood in your stools.
• Use a reliable contraceptive during treatment and for one month after stopping the medicine to avoid pregnancy.
• Erloren can make your skin sensitive to sunlight. Always apply sunscreen and wear protective clothing when outdoors.
• Avoid smoking, as it can reduce the effectiveness of the medicine and may require dose adjustments.
• Do not take Erloren with stomach acid-lowering medications (like antacids or ranitidine), as they can interfere with its absorption.
• Inform your doctor immediately if you notice mouth ulcers, vision changes, or worsening respiratory symptoms like cough or shortness of breath.
• Regular blood tests may be required to monitor liver function during treatment.

✔️ Dosage & Administration of Erloren 150

NSCLC: Take 150 mg daily on an empty stomach (at least 1 hour before or 2 hours after food). Continue until disease progression or unacceptable toxicity.

Pancreatic Cancer: Take 100 mg daily in combination with gemcitabine, on an empty stomach. Continue until disease progression or unacceptable toxicity.

Dose Adjustments:

• CYP3A4 Inhibitors: Reduce Erloren dosage in 50 mg increments if used with strong inhibitors like ketoconazole or ciprofloxacin.
• CYP3A4 Inducers: Increase Erloren dosage in 50 mg increments every 2 weeks (up to a maximum of 450 mg) when used with strong inducers like rifampin or carbamazepine. Avoid concomitant use if possible.
• Cigarette Smokers: Increase dosage by 50 mg increments every 2 weeks, up to 300 mg daily. Reduce to standard dose (150 mg or 100 mg daily) upon cessation of smoking.
• Pediatric: Safety and efficacy not established.
• Geriatric: No significant differences in safety or efficacy between patients aged 65+ and younger individuals.

✔️ Interaction

• Anticoagulants: Interaction with warfarin and other coumarin-derived anticoagulants may increase the International Normalized Ratio (INR) and risk of bleeding.
• CYP3A4 Inhibitors: Drugs like ketoconazole and ciprofloxacin increase Erloren exposure.
• CYP3A4 Inducers: Drugs like rifampin significantly reduce Erloren exposure.
• Gastric pH-Altering Drugs: Omeprazole and ranitidine decrease Erloren absorption.

✔️ Contraindications:

Hypersensitivity.

✔️ Pregnancy & Lactation

• Pregnancy (Category D): May cause fetal harm. Avoid use in pregnant women unless necessary.
• Breastfeeding: It is unknown whether Erloren is excreted in breast milk. Discontinue nursing or discontinue Erloren, considering the importance of the drug to the mother.

✔️ Precautions & Warnings

• Interstitial Lung Disease (ILD): Occurs in 1.1% of patients. Discontinue if ILD is diagnosed.
• Renal Failure: Monitor renal function, especially in patients at risk of dehydration. Withhold Erloren for severe renal toxicity.
• Hepatotoxicity: Perform periodic liver tests. Discontinue for worsening or severe liver damage.
• Other Risks: Monitor for gastrointestinal perforations, bullous skin disorders, and myocardial infarctions in patients with pancreatic cancer.

✔️ Storage:

Store in a dry place at temperatures below 30°C. Protect from light and moisture.